Who is Habil Khorakiwala?

Habil Khorakiwala is the founder and executive chairman of Wockhardt Ltd, a Mumbai-based pharmaceutical and biotechnology company. Born in 1942, he took charge of a small family-owned drug unit after a master's degree at Purdue University and built it into a multinational.

What is Habil Khorakiwala's net worth?

Forbes' real-time billionaires tracker estimated his net worth at about US$1.8 billion on 10 November 2026. Most of it comes from the promoter group's roughly 49% stake in Wockhardt, held largely through family trustee companies.

How did Habil Khorakiwala start Wockhardt?

His father, who ran the Akbarallys stores in Mumbai, bought a small firm called Worli Chemical Works in 1959. Habil took charge after returning from Purdue in 1966, when it had about 20 employees and sales of about Rs 4 lakh; the company dates its founding to 1967 and took the Wockhardt name in 1973.

What is Habil Khorakiwala's education?

He holds a pharmacy degree from L.M. College of Pharmacy, Ahmedabad, and a master's degree from Purdue University in the United States (1966), and attended the Advanced Management Program at Harvard Business School. Purdue gave him an honorary doctorate in 2010.

What was the Wockhardt debt crisis?

After six overseas acquisitions, Wockhardt was hit in 2008-09 by losses on currency derivatives and defaulted on US$110 million of foreign currency convertible bonds in October 2009. It entered corporate debt restructuring, sold its hospitals, animal health and nutrition businesses, settled bondholders under Bombay High Court directions and planned its exit from restructuring in 2012-13.

What were the US FDA problems at Wockhardt?

The US FDA placed Wockhardt's Waluj and Chikalthana plants under import alerts in 2013 and its Ankleshwar plant in 2016, citing manufacturing and data-integrity failures. All three remained on the FDA's import alert list as of November 2026, and Wockhardt exited US generics in July 2025.

Zaynich (cefepime and zidebactam) is an intravenous antibiotic discovered and developed by Wockhardt. India's drug regulator and the US FDA approved it in late May 2026 for complicated urinary tract infections; the company describes it as the first new chemical entity fully developed by an Indian company to win US FDA approval.

Who will succeed Habil Khorakiwala?

He remains executive chairman on a term running to 28 February 2030. His son Murtaza has been managing director since April 2009, son Huzaifa is executive director and runs Wockhardt Foundation, and daughter Zahabiya runs Wockhardt Hospitals and sits on the Wockhardt board.

Habil Khorakiwala: Wockhardt Founder's Story

Key facts
Born	1942, in a Dawoodi Bohra trading family of Bombay (now Mumbai); the exact date is not reliably published, and Purdue University’s citation gives Palanpur, Gujarat, as his birthplace [26][33]
Family roots	Palanpur, Gujarat; the family moved to Bombay in 1896 and opened the shop that became Akbarallys [34]
Education	B.Pharm, L.M. College of Pharmacy, Ahmedabad; MS, Purdue University (1966); Advanced Management Program, Harvard Business School [22][26]
Family	Wife Nafisa; sons Huzaifa and Murtaza and daughter Zahabiya, all in the group’s businesses [39][10]
Company	Wockhardt Ltd (founder and executive chairman); the family separately owns Wockhardt Hospitals [10][89]
Wealth	About US$1.8 billion (Forbes real-time estimate, 10 November 2026) [29]
Known for	Building an Indian pharma multinational, surviving a near-fatal debt crisis, and a 25-year bet on discovering new antibiotics [30][37]

On 11 March 2011, a judge of the Bombay High Court admitted a petition to wind up Wockhardt Ltd. The company had failed to repay US$110 million of bonds, a group of foreign funds wanted its assets sold, and one of the bondholders on the other side was an arm of a rival Indian drug maker. [53] The man who had built Wockhardt over four decades was 68. He had already handed the managing director’s chair to his son, sold his hospitals and put his baby-food brands on the block. [8][49]

Fifteen years later, at the end of May 2026, the US Food and Drug Administration approved Zaynich, an antibiotic for drug-resistant infections that was discovered in Wockhardt’s laboratories in Aurangabad. The company calls it the first new chemical entity fully developed by an Indian company to win US approval. [28] Habil Khorakiwala, now 83, was still executive chairman. [10]

Between those two dates lies one of the stranger stories in Indian business: a founder who was nearly liquidated, then barred from his largest export market by the same US regulator, and who kept paying for drug discovery through all of it. This is that story, including the parts that do not flatter him.

Where it began

Habil Khorakiwala was born in 1942 into a Dawoodi Bohra business family in Bombay. In his memoir he calls himself “a boy from Bombay” and describes a joint family with a strict father and a gentle mother. [33] (Sources differ on the birthplace: Purdue University’s honorary degree citation says Palanpur, the family’s home town in Gujarat. [26])

The family’s story in the city began in 1896, when his grandfather Taherbhai Khorakiwala came from Palanpur and opened a provision shop named Akbarally’s, after an uncle. [34] Habil’s father, Fakhruddin T. Khorakiwala, a law graduate who took part in the Quit India movement, took charge in the mid-1950s and turned the shop into Akbarallys, one of Bombay’s first department stores. [34][40][42]

Fakhruddin was more than a shopkeeper. As Sheriff of Mumbai in 1992-93, after the riots that followed the demolition of the Babri Masjid, he organised a human chain across the city and helped start the peace committees that grew into Mumbai’s mohalla committees. He later served as chancellor of Jamia Millia Islamia, and died in July 2011 at 93. [40][41]

Habil was the eldest of three brothers. [40][31] By his own account, an uncle steered him towards pharmacy. He studied at L.M. College of Pharmacy in Ahmedabad, then left for Purdue University in Indiana, where he took a master’s degree in 1966. [33][26] The memoir records that before he sailed, he resolved to treat the American university as “a stepping stone rather than a final destination”. [33] He came home.

The first break

The break was a business nobody else in the family wanted.

In 1959 Fakhruddin had bought a small drug maker, Worli Chemical Works, as a supplier for the pharmacy counter at Akbarallys. [30] It made remedies for common ailments. The wider family preferred retail. As Khorakiwala told Business Standard decades later, the unit “had no takers”. [31]

When he took charge after returning from Purdue, it had about 20 employees and annual sales of roughly Rs 4 lakh. [39][31] The company today dates its founding to 1967; the name Wockhardt arrived in 1973. [21][33] The name is often said to mean “work hard” in German. It does not, and by one account it was chosen simply because it sounded German enough to suggest quality. [39][31]

Two early decisions shaped everything after.

The first was timing. India’s Patents Act of 1970 stopped recognising product patents on medicines, which let Indian firms legally make their own versions of foreign drugs. Khorakiwala’s memoir treats this law as the first turning point of his career. [33] Wockhardt launched the painkiller Proxyvon in 1972, and in 1979 it brought povidone-iodine to India under licence. [21]

The second was geography. The Worli premises were cramped, and Maharashtra was offering incentives for industry in backward districts. Khorakiwala wanted to build in Aurangabad, more than 300 km away. His father preferred Mumbai. Habil has written that he had to argue his case, and that Wockhardt’s was the first pharmaceutical plant in the town. [35] The company moved there in 1976 and commissioned its first modern plant at Chikalthana in 1979. [33][21] Aurangabad is still the heart of the company.

His father’s advice, which opens the memoir, was short: do not be afraid of making mistakes, but never repeat them. [34] He would test the first half of that sentence more thoroughly than most.

Building the empire

Going public on the eve of a riot

By the late 1980s Wockhardt was a mid-sized formulations company with ambitions outside tablets. In 1989 it opened a medical centre in Kolkata, and in the early 1990s a heart hospital in Bengaluru, the start of what became Wockhardt Hospitals. [89]

The public issue came in December 1992. According to the memoir, Khorakiwala closed it three days early, on 5 December, against his merchant banker’s advice. The issue was already oversubscribed four times, and he feared trouble at Ayodhya. The Babri Masjid was demolished the next day; the markets fell on 7 December. [33] A few months later his father was organising peace marches in a burning city.

The 1991 reforms changed how he saw the business. “To face global competition we must go global,” he later wrote, asking why Indian pharma could not do what Indian IT was doing. [35] Wockhardt became the first Indian pharmaceutical company to raise money abroad through global depository receipts. [47] In 1998 it bought Merind, a drug company in which the Tata group held the controlling stake, and a small British firm, Wallis Laboratory. [21][48] At the turn of the century the group was reorganised, and the present Wockhardt Ltd was incorporated in 1999. [21]

The biotech bet

Most Indian drug makers of that period grew by copying small-molecule drugs. Khorakiwala pushed early into biotechnology, the same frontier that Kiran Mazumdar-Shaw was pursuing in Bengaluru.

Wockhardt launched its first recombinant product, the hepatitis B vaccine Biovac-B, in 2000. [21] In August 2003 it launched Wosulin, becoming the first Indian company to sell recombinant human insulin made with its own technology. [46] In February 2009 came Glaritus, a version of the long-acting insulin glargine; the company said it was the first in the world after the original inventor to launch one. [20]

Around the turn of the century he also set up a drug-discovery team and pointed it at antibiotics, reasoning that big drug companies would sooner or later leave the field. [36] He has described being warned by a senior scientist that discovery research could be “a bottomless pit”. [35] That decision produced nothing saleable for more than twenty years. It comes back at the end of this story.

The buying spree, 1998-2007

Then came the buying.

1998: Wallis Laboratory, UK. [48]
2003: CP Pharmaceuticals, an injectables maker in Wrexham, Wales, for about £10.9 million. [45]
2004: Esparma of Germany, for about US$11 million. [47]
2006: Pinewood Laboratories of Ireland, for US$150 million in cash. Khorakiwala said Europe would now bring in almost half of Wockhardt’s sales. [44]
2006: Dumex India, which brought the nutrition brands Farex and Protinex. [93]
2007: Negma Laboratories of France, for US$265 million in cash, the third acquisition in under a year. [43]
2007: Morton Grove Pharmaceuticals, a liquid-medicines maker near Chicago, for about US$38 million. [47]

Sales in 2006 were Rs 1,729 crore, about 60% of it from Europe, and the chairman was talking of Rs 4,500 crore by 2009. [48] In January 2007 he became president of FICCI, the industry chamber, serving until February 2008. [86][87] Purdue named him a distinguished alumnus that year. [27]

Almost all of this expansion was paid for with borrowed money. The acquisitions were financed with loans and with US$110 million of zero-coupon foreign currency convertible bonds (FCCBs) issued in October 2004. The bonds would turn into shares if Wockhardt’s price stayed above about Rs 486; if not, the company would have to repay them at a premium in October 2009. [47]

How the wealth is held

Khorakiwala’s fortune is, in effect, his family’s stake in Wockhardt. He personally owns less than 0.4% of the company. The promoter group held 49.08% on 31 March 2026, of which about 40% sits with Themisto Trustee Company and most of the rest with other family trustee companies. [9] In 2014, when the family owned about 74%, the shares were moved by gift deed into family-controlled partnership firms, which Business Standard reported was part of a succession plan. [83]

The stake has shrunk because the company has repeatedly sold new shares to stay funded: the promoter holding was about 72% in March 2020 and about 49% in September 2026. [81] Part of the promoter holding is pledged to lenders: 18.82% of it at the end of March 2026. [9] Wockhardt’s market value was about Rs 33,000 crore on 9 November 2026. [92] Forbes’ real-time tracker put Khorakiwala’s net worth at about US$1.8 billion the next day. [29]

Wockhardt Hospitals is separate. It is owned by the family outside the listed company and run by his daughter, Zahabiya. [89]

The setbacks and failures

2008-09: the derivatives and the default

In February 2008 the family tried to list Wockhardt Hospitals. The issue drew bids for only about a fifth of the shares and was withdrawn. [89][47] It was an early sign that the easy-money years were over.

Then the rupee swung, and Wockhardt’s currency derivative contracts went badly wrong. For calendar 2008 the company reported mark-to-market foreign exchange losses of Rs 581 crore and a net loss. [58] Banks squeezed credit. The share price, Rs 419 on 1 January 2008, was Rs 68 by March 2009. [59]

“This is the worst crisis in our lifetime,” Khorakiwala told Business Standard in April 2009, blaming a combination of factors that “caught us unawares”. He defended the acquisitions themselves, saying all were doing well. [32] Total debt when the company went into corporate debt restructuring (CDR) is reported at about Rs 3,800 crore; other accounts put the peak between Rs 3,200 crore and Rs 4,200 crore. [59][48][47]

On 1 April 2009 the board announced that Habil would remain chairman while Murtaza became managing director and Huzaifa executive director. The company called it a long-term succession plan. [8] Lenders, led by ICICI Bank, approved the CDR package in June 2009. [48]

With the share price far below the conversion price, the FCCB holders wanted cash. The bonds fell due in October 2009. Wockhardt did not pay. [47][53]

Selling the family silver

What followed was three years of selling.

In August 2009, Fortis Healthcare bought 10 Wockhardt hospitals in Mumbai, Bengaluru and Kolkata for Rs 909 crore. [49] The animal health business went to France’s Vetoquinol for about Rs 170 crore, and the German unit Esparma was sold. [50][47]

The nutrition business was first sold to Abbott in July 2009 for about Rs 625 crore. Bondholders challenged the sale in court, and in April 2010 the deal was called off. [50] Sixteen months later, in August 2011, Wockhardt agreed to sell the same business to Danone for a reported Rs 1,576 crore, more than double the Abbott price. The completed sale in July 2012 was reported at Rs 1,280 crore; the reports do not explain the difference. [51][52]

Forbes India later quoted his explanation of how he got through it. In the darkest hour, he said, you can be paralysed by the size of the problem or you can anticipate the worst case and deal with it. “I choose the latter.” Selling the hospitals, he added, was not an emotional barrier. [30] On derivatives, his conclusion was blunt: “We don’t understand hedging and will not risk our business.” [31]

2013: the regulator

The recovery was fast. Wockhardt’s generic of the heart drug Toprol-XL and other products took off in the United States, and revenue reached Rs 5,721 crore in 2012-13, about half of it from the US. [30] By March 2013 the company was valued at nearly Rs 22,000 crore. In September 2012 Khorakiwala told shareholders it would prepay its lenders and leave CDR within the financial year. [61][60]

Then, in May 2013, the US FDA banned imports from the Waluj plant, and in November from Chikalthana. The shares lost more than 70% of their value that year. [61][62] The details are in the next section. The business consequence was a lost decade: revenue fell to Rs 4,830 crore the following year and kept sliding, and Wockhardt reported a net loss in eight of the nine years from 2016-17 to 2024-25. [30][81]

To keep going, the company sold again. In 2020, 62 domestic brands and a plant at Baddi went to Dr Reddy’s Laboratories for up to Rs 1,850 crore. [16] The Wrexham plant earned contract income filling COVID-19 vaccine vials for the UK government from 2020. [17] A rights issue in March 2022 raised about Rs 748 crore. [77] In July 2025 Wockhardt gave up on US generics altogether, putting Morton Grove Pharmaceuticals and Wockhardt USA into voluntary liquidation. [14]

Controversies and allegations

US FDA import alerts and data-integrity findings (2013 onwards)

Allegation: After inspecting the Waluj plant in March 2013, the US FDA placed it on import alert in May 2013 and issued a warning letter in July. As reported from the letter, inspectors said the firm had delayed or limited the inspection, that an analyst poured the contents of unlabelled vials down a drain, that about 75 torn batch records were found in a waste area showing failed visual inspections, and that urinals drained into an open drain near a clean-room entrance. The FDA described the unreliability of the plant’s data as a serious manufacturing deficiency. [64][65][63] The Chikalthana plant was placed on import alert in November 2013, and a second warning letter alleged unofficial “trial” testing of samples and deleted data. [63][1] The UK regulator, MHRA, recalled 16 Waluj-made medicines as a precaution in 2013 and restricted the GMP certificates of Indian plants, while stating there was no evidence that the medicines were defective. [6][66]

Response: Wockhardt said it had hired US consultants and begun remediation. Khorakiwala estimated the Waluj ban could cost up to US$100 million a year in sales. [61][65]

What happened next:

The UK regulator restored an unrestricted GMP certificate for Chikalthana in November 2015. [67]
The FDA placed the Ankleshwar bulk-drug plant on import alert in August 2016, later citing data-integrity failures. [68][1]
Warning letters followed for the group’s plants in Wrexham (2016) and Morton Grove, Illinois (2017). [69]

Status: Unresolved for the US. As of November 2026, Waluj, Chikalthana and Ankleshwar all still appear on the FDA’s Import Alert 66-40 list. [1] Wockhardt no longer sells generics in the United States. [14]

SEBI case on delayed disclosure (2013 inspection; settled 2023)

Allegation: SEBI issued a show-cause notice in September 2022 alleging that Wockhardt did not promptly disclose the FDA’s March 2013 inspection observations to investors, and that its directors failed in supervision of the insider-trading code. A former senior executive was separately penalised by SEBI for selling shares before the news became public. [70][3]

Response: The company and the three Khorakiwalas applied for settlement.

Status: Closed. Under a settlement order dated 22 May 2023, Wockhardt paid about Rs 36.7 lakh and Habil, Murtaza and Huzaifa Khorakiwala about Rs 13.3 lakh each, Rs 76.68 lakh in all, without admitting or denying the findings. [3][70]

The FCCB default and winding-up petitions (2009-2012)

Allegation: After Wockhardt failed to redeem US$110 million of FCCBs in October 2009, about three-quarters of bondholders accepted a restructuring offer. A group led by the hedge fund QVT did not, and the bond trustee petitioned the Bombay High Court to wind up the company. Sun Pharma Global, an arm of Dilip Shanghvi’s group, was among the holdouts. Several banks, including DBS, Barclays, Calyon and Lehman Brothers’ derivatives arm, filed their own petitions over loans and derivative contracts. [48][53][56][57]

Response: Wockhardt said banks had unilaterally terminated the derivative contracts and that it had legal advice that the claims could be disputed. It appealed the winding-up order. [58][7]

What happened next:

A single judge admitted the trustee’s petition on 11 March 2011. [53]
A division bench stayed that order on 23 March 2011, on condition that Wockhardt deposit Rs 115 crore. [54]
In October 2011 the court directed payment in instalments by 31 August 2012 and warned that a liquidator would be appointed on default. [55]
Lehman’s unit withdrew its petition in February 2012 after an out-of-court settlement. [57]

Status: Resolved. By August 2012 almost all the bonds had been repaid and the company announced plans to exit CDR in 2012-13. [59][60] No court found wrongdoing by Khorakiwala; this was a commercial default, later cured.

Allegation: In August 2022 the US Department of Justice filed a civil complaint alleging that Morton Grove Pharmaceuticals, Wockhardt’s Illinois subsidiary, made and distributed adulterated drugs, citing repeat manufacturing violations found over several FDA inspections. [2]

Response: The defendants agreed to a consent decree of permanent injunction. The department’s own statement says the claims are allegations only and that there was no determination of liability. [2]

Status: Closed by consent decree. Wockhardt had already decided to stop manufacturing at the site, and the subsidiary went into Chapter 7 liquidation in July 2025. [14][79]

US generic drug price-fixing lawsuit (2019 onwards)

Allegation: In May 2019 a coalition of 44 US states led by Connecticut sued Teva and 19 other drug makers, alleging a conspiracy to fix prices of more than 100 generic medicines. Wockhardt USA LLC is named as a defendant. [4]

Response: Wockhardt told the stock exchanges it denied the accusation and was defending the case, that it made only two of the listed products, and that its exposure was minimal. [5]

Status: Pending, with no finding against Wockhardt. Several other defendants have settled, and the states said in August 2026 they were preparing for trial in 2027. [80] Wockhardt USA has been in liquidation since July 2025. [14]

The rent paid to the SEBI chief (2024)

Allegation: In September 2024 the Congress party alleged that Carol Info Services, a company of the Khorakiwala promoter group, had paid rent of about Rs 2.16 crore between 2018 and 2024 for a Mumbai property owned by Madhabi Puri Buch, then chairperson of SEBI, while SEBI was dealing with matters involving Wockhardt. The party suggested a conflict of interest. [72]

Response: Wockhardt said the allegations were “completely baseless and misleading”. Ms Buch said the claims were false, that the rent was at market rates and that she had not dealt with Wockhardt files. [73][72]

Status: No finding against Wockhardt or the family. On 28 May 2025 the Lokpal disposed of the complaints against Ms Buch, including this one, calling the allegations unverified and flimsy. [74] It remains an unproven political allegation.

The hospital COVID cluster (April 2020)

Allegation: In April 2020 Mumbai’s civic body declared Wockhardt Hospital at Mumbai Central a containment zone after 26 nurses and three doctors tested positive for COVID-19. A senior civic official said the hospital should have taken precautions and announced an inquiry; a nurses’ union alleged delayed testing and inadequate protective equipment. [75][76]

Response: The hospital administration denied the staff allegations. [75]

Status: An inquiry was announced; no findings appear to have been published. The hospital company is separate from the listed Wockhardt Ltd. [75][89]

Shareholder pushback (2023)

Allegation: This is a governance dispute, not an accusation of wrongdoing. At the August 2023 annual meeting, minority shareholders voted down a proposal for Wockhardt to borrow up to Rs 1,600 crore from the promoters’ own finance company, by 50.13% to 49.87%. [71]

Response: The company had put the facility forward as a source of funds from its promoters. Nine other resolutions at the meeting passed. [71]

Status: The resolution failed. Wockhardt instead raised Rs 480 crore in March 2024 and about Rs 1,000 crore in November 2024 by selling shares to institutions. [78][15] At the 2025 meeting, about one in five institutional votes went against related-party transactions, which still passed. [25]

As of 10 November 2026, no court or regulator has made a finding of fraud against Habil Khorakiwala. The open items are the US import alerts and the US price-fixing suit.

Giving back

The family’s philanthropy runs mainly through Wockhardt Foundation, formed in 2008 from the company’s CSR department and run by Huzaifa Khorakiwala. When his eldest son asked to run it, Habil’s reported answer was, “Go ahead and do it.” [84][30]

Its flagship is Mobile 1000, a fleet of medical vans that take a doctor and free medicines to villages. The foundation had 110 vans in 15 states in 2017 and launched its 200th in 2019. [84][85] Huzaifa told shareholders in August 2025 that 185 mobile clinics in 21 states had treated about 40 million patients over 12 years. [24] These are the foundation’s own figures. Much of the money is raised from outside partners, including public-sector companies. [84]

Other programmes include toilets, e-learning in schools, toy libraries and children’s heart surgery. [85] In Aurangabad, the group set up Wockhardt Global School in 2015 as a non-profit. [91]

Khorakiwala served a five-year term as chancellor of Jamia Hamdard university in Delhi from December 2014; a successor took office in August 2020. [22][88] His 2017 memoir, Odyssey of Courage, carries a foreword by Muhammad Yunus. [34] In 2012 he told an interviewer he wanted, in retirement, to “sit back and enjoy the sheer joy of giving”. [31] He has not retired.

No entry for him was found in the Hurun philanthropy lists checked for this profile, so no personal giving figure is given here.

Succession

The succession plan was written in the worst month of the company’s life. Since April 2009, Dr Murtaza Khorakiwala, a doctor with an MBA, has been managing director, and Huzaifa, a Yale management graduate, executive director. [8][10] Zahabiya, who studied at New York University and the Indian School of Business, runs Wockhardt Hospitals, which today lists hospitals in Mumbai, Mira Road, Nagpur and Rajkot, and has been a non-executive director of Wockhardt since 2017. [10][94] In 2026 she took charge of the team preparing to sell Zaynich in the United States. [37][10]

But the founder has not left. Shareholders were asked in June 2024 to reappoint him executive chairman for five years, to 28 February 2030, and the 2026 annual meeting was asked to approve higher pay for the remainder of the term. [11][10]

What the next generation inherits is no longer a generics exporter. In January 2020 Wockhardt won Indian approval for Emrok, its first home-grown antibiotic. [18] Miqnaf, a three-day pneumonia treatment, was approved in January 2025. [19] Zaynich followed in May 2026, in India and the United States within days of each other, after a global trial in which, by the company’s account, it showed a higher cure rate than the standard drug meropenem. [90][28]

The company says it has spent about US$800 million on antibiotic research over roughly 25 years and has six drug candidates to show for it. [37][38][23] Large Western drug makers have mostly abandoned the field because new antibiotics are used sparingly and earn little. “For them it is not viable,” Khorakiwala told investors in 2026. “For us, it very much is.” [23]

Whether that proves true is not yet known. Wockhardt returned to profit in 2025-26, with a net profit of Rs 199 crore on revenue of Rs 3,373 crore, and stayed profitable in the first half of 2026-27. [12][82] As of early November 2026 the company was still reporting pre-launch spending on Zaynich, and its European application was under review. [82][13] The discovery has been approved. The business case has not yet been proved.

For readers who follow the sector, CapitalVia’s profiles of Cyrus Poonawalla, Murali Divi and Pankaj Patel show three very different routes through Indian pharma, and there is more market reading on the Insights page.

What their journey teaches

The business nobody wants can be the best one to inherit. Worli Chemical Works had 20 workers and no takers in a family of retailers. Nobody was watching, so he could move it to Aurangabad, rename it and rebuild it his way. [31][35]
Borrowing can turn a good strategy into a fatal one. Khorakiwala still says the acquisitions were sound, and several were. What nearly killed Wockhardt was how they were paid for: convertible bonds that assumed a rising share price, and currency contracts the management later admitted it did not understand. [32][31][47]
Decide what you will sell before you are forced to. He sold hospitals he had spent twenty years building and brands he had only just bought, and kept the laboratories. “Never sacrifice any part of the future to save the present,” he told Forbes India. [30]
Quality systems fail long before the regulator arrives. The 2013 FDA findings were about torn records and deleted test data, basic discipline on the factory floor. Thirteen years later the plants are still on the import alert list. A reputation for cutting corners in manufacturing costs more than any debt crisis, and takes longer to repair. [64][1]
A long bet needs a founder who can be wrong for decades. The antibiotic programme earned nothing through a default, a regulatory ban and eight years of losses. A professional chief executive would probably have been made to shut it. Only an owner with control could keep paying. The same control is what minority shareholders pushed back against in 2023. Both things are true. [37][71][81]

A profile for general reading, based on public records and reporting as of 10 November 2026. Not investment, tax or legal advice.

Habil Khorakiwala: Wockhardt Founder's Story

Where it began

The first break

Building the empire

Going public on the eve of a riot

The biotech bet

The buying spree, 1998-2007

How the wealth is held

The setbacks and failures

2008-09: the derivatives and the default

Selling the family silver

2013: the regulator

Controversies and allegations

US FDA import alerts and data-integrity findings (2013 onwards)

SEBI case on delayed disclosure (2013 inspection; settled 2023)

The FCCB default and winding-up petitions (2009-2012)

US generic drug price-fixing lawsuit (2019 onwards)

The rent paid to the SEBI chief (2024)

The hospital COVID cluster (April 2020)

Shareholder pushback (2023)

Giving back

Succession

What their journey teaches

Sources (94)

Frequently asked questions

More stories

Where it began

The first break

Building the empire

Going public on the eve of a riot

The biotech bet

The buying spree, 1998-2007

How the wealth is held

The setbacks and failures

2008-09: the derivatives and the default

Selling the family silver

2013: the regulator

Controversies and allegations

US FDA import alerts and data-integrity findings (2013 onwards)

SEBI case on delayed disclosure (2013 inspection; settled 2023)

The FCCB default and winding-up petitions (2009-2012)

US Justice Department consent decree, Morton Grove (2022)

US generic drug price-fixing lawsuit (2019 onwards)

The rent paid to the SEBI chief (2024)

The hospital COVID cluster (April 2020)

Shareholder pushback (2023)

Giving back

Succession

What their journey teaches

Sources (94)

Frequently asked questions

More stories